Literature DB >> 3965857

Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure.

B Gonen, A P Goldberg, H R Harter, G Schonfeld.   

Abstract

Patients with renal failure on maintenance hemodialysis have accelerated rate of atherosclerosis. This, and the fact that chemically modified low-density lipoproteins (LDL) have a better capacity than native LDL to stimulate cholesteryl ester accumulation within macrophages in the vessel wall, led us to examine the possibility that some alteration in apo-LDL may take place in chronically uremic patients. We isolated LDL (d = 1.019 - 1.063 g/mL) from 18 patients with chronic renal failure and from 13 normolipidemic controls and compared the interactive properties of the different LDL preparations with cultured fibroblasts. Our results show that "uremic" LDL associates less, is degraded less, and has diminished ability to stimulate cholesteryl ester formation in fibroblasts when compared to normal LDL. LDL carbamylated in vitro showed interactive properties with fibroblasts similar to those of uremic LDL. Uremic LDL was not taken up by scavenger receptors present on rat peritoneal macrophages, similarly to normal LDL. However, the decrease in uptake by fibroblasts of uremic LDL may increase the residence time of these particles within the subendothelial region of the vessel wall, ultimately resulting in increased atherogenicity. Carbamylation of lysine residues of apoB in vivo, abnormal catabolism of LDL due to the absence of functional renal tissue, or triglyceride enrichment of LDL are among the possible explanations for the abnormal properties of uremic LDL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965857     DOI: 10.1016/0026-0495(85)90052-6

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  8 in total

1.  Endonuclease G mediates endothelial cell death induced by carbamylated LDL.

Authors:  Eugene O Apostolov; Debarti Ray; Wilson M Alobuia; Marina V Mikhailova; Xiaoying Wang; Alexei G Basnakian; Sudhir V Shah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-01       Impact factor: 4.733

2.  Carbamylated Low-Density Lipoprotein and Thrombotic Risk in Chronic Kidney Disease.

Authors:  W H Wilson Tang; Stanley L Hazen
Journal:  J Am Coll Cardiol       Date:  2016-10-11       Impact factor: 24.094

3.  The pattern of apolipoprotein A-I lysine carbamylation reflects its lipidation state and the chemical environment within human atherosclerotic aorta.

Authors:  Shawna Battle; Valentin Gogonea; Belinda Willard; Zeneng Wang; Xiaoming Fu; Ying Huang; Linda M Graham; Scott J Cameron; Joseph A DiDonato; John W Crabb; Stanley L Hazen
Journal:  J Biol Chem       Date:  2022-03-15       Impact factor: 5.486

4.  Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL.

Authors:  Eugene O Apostolov; Sudhir V Shah; Debarti Ray; Alexei G Basnakian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-20       Impact factor: 8.311

5.  Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages.

Authors:  Eugene O Apostolov; Ercan Ok; Samuel Burns; Safia Nawaz; Alena Savenka; Sudhir V Shah; Alexei G Basnakian
Journal:  J Atheroscler Thromb       Date:  2013-09-25       Impact factor: 4.928

Review 6.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

7.  Endogenous carbamylation of renal medullary proteins.

Authors:  J'Neka S Claxton; Pablo C Sandoval; Gary Liu; Chung-Lin Chou; Jason D Hoffert; Mark A Knepper
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

8.  Impact of Uremic Toxins on Endothelial Dysfunction in Chronic Kidney Disease: A Systematic Review.

Authors:  Eva Harlacher; Julia Wollenhaupt; Constance C F M J Baaten; Heidi Noels
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.